Semaia has programs in signal transduction pathway-base oncology target discovery.

History:

Acquired by Hybrigenics in 2003, they now act as a subsidiary. They now appear to be in liquidation (2008).

Employment

Email:

Fax:

Mail:

General Info:

Ticker: subsidiary

Employees:

Regions:
Europe

Research Focus:
Disease Therapeutics-Research

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: